A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs MCS 110 (Primary) ; PDR 001 (Primary)
- Indications Breast cancer; Endometrial cancer; Malignant melanoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 May 2017 Planned number of patients changed from 175 to 196.
- 27 Feb 2017 Planned primary completion date changed from 1 Jun 2019 to 29 Jul 2018.
- 22 Nov 2016 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.